secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269536
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q3 net loss $74.1M, cash $596.4M; appoints two directors
---------------------------------------------------------------------------

- Net loss $74.1M ($0.43 per share) vs $88.1M ($0.63) in Q3 2024.
- Cash, cash equivalents and investments $596.4M at Sep 30, 2025; expected to fund operations into 2029.
- R&D expenses $68.3M, down from $76.6M YoY on streamlining and cost avoidance.
- Board appointed Lonnel Coats and Habib Dable, former biotech CEOs, effective Nov 4, 2025.
- Continued Phase 3 ReDiscover-2 trial and Phase 1/2 ReInspire trial in vascular malformations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000119312525269536/0001193125-25-269536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000119312525269536/rlay-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer